<DOC>
	<DOC>NCT01287325</DOC>
	<brief_summary>This study evaluates the efficacy and safety of two weeks treatment of DNK333 in patients with COPD and cough.</brief_summary>
	<brief_title>Efficacy of DNK333 in Patients With COPD and Cough</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Mild to moderate COPD Forced expiratory volume in 1 second (FEV1) â‰¥30% predicted FEV1/FVC (forced vital capacity) &lt;70% Significant amount of cough and minimal amount of sputum production, both as judged by self reporting Exclusion criteria: Upper or lower airway infection within 4 weeks prior to screening COPD exacerbation within 4 weeks prior to screening Past history or current diagnosis of congestive heart failure, cirrhosis or hepatic failure History of lung cancer or pulmonary resection/thoracic radiotherapy Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Chronic obstructive pulmonary disease</keyword>
	<keyword>Cough</keyword>
	<keyword>DNK333</keyword>
</DOC>